+

WO2018170761A1 - Recombinant adeno-associated virus for knocking down expressions of mir-140, mir-152 and mir-185 - Google Patents

Recombinant adeno-associated virus for knocking down expressions of mir-140, mir-152 and mir-185 Download PDF

Info

Publication number
WO2018170761A1
WO2018170761A1 PCT/CN2017/077603 CN2017077603W WO2018170761A1 WO 2018170761 A1 WO2018170761 A1 WO 2018170761A1 CN 2017077603 W CN2017077603 W CN 2017077603W WO 2018170761 A1 WO2018170761 A1 WO 2018170761A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
tud
associated virus
recombinant adeno
recombinant
Prior art date
Application number
PCT/CN2017/077603
Other languages
French (fr)
Chinese (zh)
Inventor
毛吉炎
Original Assignee
深圳市博奥康生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市博奥康生物科技有限公司 filed Critical 深圳市博奥康生物科技有限公司
Priority to PCT/CN2017/077603 priority Critical patent/WO2018170761A1/en
Publication of WO2018170761A1 publication Critical patent/WO2018170761A1/en

Links

Definitions

  • the present invention belongs to the field of molecular biology and biomedicine technology, and particularly relates to a recombinant adeno-associated virus which knocks down the expression of miR-140, mi R-152 and miR-185.
  • MicroRNAs are a class of endogenous, non-coding RNAs found in eukaryotes, typically between 22 and 25 nt in size. miRNAs are widely distributed in plants, animals, and multicellular organisms, and can Play an important regulatory role, and in the study of human miRNAs, it is found that the expression of miRNA in normal tissues and tumor tissues is significantly different, some miRNAs are lowly expressed in tumor tissues, and some are highly expressed in tumor tissues. This suggests that miRNAs play a crucial role in tumorigenesis.
  • miR-140 is closely related to the development of various diseases, such as bone and joint diseases, liver diseases, pituitary adenomas, testicular development, head and neck tumors, ovarian and breast diseases. miR-140 can inhibit the proliferation and invasion and metastasis of hepatocellular carcinoma by targeting TG FBR1 and other gene expression. miR-140 is highly expressed in articular cartilage and plays a vital role in the pathogenesis of osteoarthritis.
  • miR-152 is a kind of Functional miRNAs, studies have found that miR-152 is associated with methylation, such as methyltransferase DNMT1 content and enzyme activity, miR-152 can be methylated by endometrial cancer DNA into a silent gene, and its Related to the development of cancer, it is a tumor suppressor microRNA, which is associated with many diseases such as preeclampsia, trophoblastic tumor, bladder cancer, gastrointestinal cancer, ovarian cancer, etc.
  • miR-185 is a 22 nt miRNA, localization Human chromosome 22ql 1.21 plays an important role as a tumor suppressor gene in the development and invasion of tumors such as colon cancer, gastric cancer, esophageal cancer, lung cancer, and liver cancer, and it also has a methylation phase.
  • the inhibition of miRNA may be through direct targeted expression DNMT1 level of methylation of the genome, and thus the regulation of the methylation status of certain modification genes, gene expression.
  • the synergy with other drugs can provide new epigenetic ideas for the treatment of cancer. technical problem
  • Tough Decoy RNA is a novel miRNA-inhibiting miRNA that inhibits miRNA by introducing double-stranded RNA to target miRNAs. Because the inserted RNA is double-stranded and has a secondary structure of stem-loops, it is resistant to intracellular nuclease degradation and inhibits miRNAs in a long-term, stable, and efficient manner.
  • Adeno-associated virus is a non-pathogenic human parvovirus that can infect a wide variety of cells, including mitotic and non-dividing cells, and is characterized by its safety, long-lasting, high-efficiency, and high specificity.
  • researchers are highly regarded and favored and are widely used in the field of biology.
  • the use of AAV as a gene therapy vector has potential advantages.
  • the technical solution adopted by the present invention is: a knockdown of miR-140, miR-152 and mi
  • the recombinant adeno-associated virus expressed by R-185 was constructed by the following methods:
  • the Tud RNA sequences specific for miR-140, 1 ⁇ 11-152 and 1 ⁇ 11-18 5 were designed to construct the recombinant plasmid pAKD-Tud-140-152. -185, and performing DNA sequencing analysis;
  • the Tud RNA sequence specific for miR-140, miR-152 and miR-185 in step a is: 5'- GCCCAAGATGATCCTAGCGCCACCTTTTT -3,.
  • step a a Kpn I and Bg III endonuclease cleavage site sequence and a transcription termination sequence are added to the selected target sequence to synthesize a complete Tud DNA sequence:
  • Tud DNA-F 5'-
  • the present invention constructs a recombinant adeno-associated virus rAAV-T ud-140-152-185 which knocks down miR-140, miR-152 and miR-185, and can stably express the target protein and high biosafety for a long time.
  • the serotype 8 adeno-associated virus (AAV8) is a transduction vector that stably expresses Tud RNA in vivo for a long time, thereby knocking down the expression of miR-140, miR-152 and miR-185.
  • FIG. 1 is a schematic diagram showing the results of quantitative PCR detection of miRNA expression levels in each group of cells, wherein a. miR-140 expression, b. miR-152 expression, c. miR-185 expression.
  • Example 1 Construction of a recombinant adeno-associated virus expressed by miR-140, miR-152 and miR-185
  • the cleavage site sequence and transcription termination sequence of Kpn I and Bgl II endonucleases were commissioned by Shanghai Yingjun Biotechnology Co., Ltd. to synthesize the complete Tud DNA sequence ij ij.
  • Tud-140-152-185 The Tud DNA template was annealed, and after annealing, a double-stranded oligonucleotide fragment having a Kpn I and Bgl II restriction sites at both ends was formed, which was labeled Tud-140-152-185.
  • the pAKD-shRNA plasmid vector was obtained by linear digestion with Kpn I and Bgl II, and an appropriate amount of the product was detected by 1% agarose gel electrophoresis and recovered.
  • the double-stranded DNA was ligated into the restriction vector according to the ligation reaction system, ligated and incubated at 4 ° C overnight, and transformed into competent E. coli DH5oc, which was plated and incubated overnight. Single colonies were picked for cultivation and sent to Shanghai Yingjun Biotechnology for sequencing. The bacteria with the correct sequencing results were cultured, and the pAKD-Tud-140-152-185 plasmid was extracted using the Promega plasmid extraction kit (endotoxin).
  • Virus packaging, purification and titer determination was obtained by linear digestion with Kpn I and Bgl II, and an appropriate amount of the product was detected by 1% agarose gel electrophoresis and recovered.
  • the double-stranded DNA was ligated
  • AAV-293 cell culture is carried out by a conventional method, and when the cells reach 70-80% fusion, the calcium phosphate method is used for virus transfection, and rAAV8 expressing Tud-140-152-185 is obtained, and virus collection is performed. Concentrate and purify.
  • the virus was titrated by a quantitative PCR method.
  • the number of viral particles of rAAV is determined by detecting the genomic copy number of the rAAV vector in the viral genome, and the titer unit is expressed in vg/ml, that is, the number of viral genomes per ml (Vims Genome).
  • the virus sample to be tested was digested with DNase and RNase at 37 ° C for 2 ⁇ 3 h, and the virus DNA was extracted and denatured in a boiling water bath for 5 min, immediately placed on ice for 2 min, and the virus sample and the standard product were diluted to different concentrations.
  • the primers used were: upstream: 5'-CCTTTCCGGGACTTTCGCTTT-3', downstream: 5,-GCAGAATCCAGGTGGCAAC A-3.
  • the reaction conditions were: denaturation at 94 ° C for 15 s, annealing at 52 ° C for 30 s, and extension at 72 ° C for 30 s, for a total of 40 cycles.
  • a standard curve was drawn based on the standard and the virus sample titer was calculated.
  • the average virus titer was calculated to be 1.05x1012 vg/ml.
  • Example 2 AAV transfection ACHN cells
  • ACHN cells were inoculated into a six-well plate, 1000000 cells per well, and the cell density was about 50% after 12 hours.
  • the virus solution was taken separately, and the virus was diluted 1000 times with DMEM complete medium to remove the medium in the 6-well plate. , add virus-containing DMEM complete medium (containing 10% fetal bovine serum), 24h
  • the miRNAs of normal ACHN cells and TuD-140-152-185 cells were extracted using the miRcute miRNA extraction and isolation kit, followed by S-Poly(T) hsa-miR-140 qPCR-assay primer set, S-Poly ( T) hsa-miR-152 qPCR-assay primer set and S-Poly(T) hsa-miR-185 qPCR-assay primer set kit for reverse transcription and tailing of miRNA to obtain the corresponding cDNA.
  • the cDNA of each of the two cells was used as a template.
  • the expression levels of miR-140, miR-152 and miR-185 were detected by real-time PCR.
  • the present invention constructs a recombinant adeno-associated virus rAAV-T ud-140-152-185 which knocks down miR-140, miR-152 and miR-185, and has a long-term stable expression of the target protein and high biosafety.
  • the adeno-associated virus (AAV8) is a transduction vector that stably expresses Tud RNA in vivo for a long time, thereby knocking down the expression of miR-140, miR-152 and miR-185.

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided is a recombinant adeno-associated virus, capable of expressing a Tud RNA for miR-140, miR-152 and miR-185, thereby knocking down the expressions of miR-140, miR-152 and miR-185.

Description

说明书 发明名称:一种敲低 miR-140、 miR-152和 miR-185表达的重组腺相  Description: A recombinant glandular phase that mimics the expression of miR-140, miR-152 and miR-185
技术领域 Technical field
[0001] 本发明属于分子生物学与生物医药技术领域, 具体涉及一种敲低 miR-140、 mi R-152和 miR-185表达的重组腺相关病毒。  [0001] The present invention belongs to the field of molecular biology and biomedicine technology, and particularly relates to a recombinant adeno-associated virus which knocks down the expression of miR-140, mi R-152 and miR-185.
背景技术  Background technique
[0002] MicroRNA (miRNA) 是在真核生物中发现的一类内源性的非编码 RNA, 大小 一般在 22-25 nt之间, miRNA广泛分布于植物、 动物和多细胞生物中, 并且能发 挥重要的调节作用, 而在人类 miRNA的研究中, 发现 miRNA在正常组织和肿瘤 组织中的表达有着显著差异, 有些 miRNA会在肿瘤组织中有低表达, 有些则在 肿瘤组织中有高表达, 这说明 miRNA在肿瘤发生过程中起了至关重要的作用。  [0002] MicroRNAs (miRNAs) are a class of endogenous, non-coding RNAs found in eukaryotes, typically between 22 and 25 nt in size. miRNAs are widely distributed in plants, animals, and multicellular organisms, and can Play an important regulatory role, and in the study of human miRNAs, it is found that the expression of miRNA in normal tissues and tumor tissues is significantly different, some miRNAs are lowly expressed in tumor tissues, and some are highly expressed in tumor tissues. This suggests that miRNAs play a crucial role in tumorigenesis.
[0003] miR-140与多种疾病的发生发展密切相关, 如骨、 关节疾病, 肝脏疾病, 垂体 腺瘤, 睾丸发育, 头颈部肿瘤, 卵巢与乳腺疾病等。 miR-140能通过靶向调节 TG FBR1等基因表达抑制肝细胞癌增殖和侵袭转移, miR-140特异性高表达于关节软 骨中, 并在骨关节炎的发病机制中发挥至关重要的作用, 在多种机制调控下, m iR-140在一些肿瘤中发挥癌基因作用, 而在另一些肿瘤中发挥抑癌作用, 并且与 多种肿瘤化疗耐药性有关; miR-152是一种具有多功能的 miRNA, 研究发现 miR- 152与甲基化相关, 如与甲基转移酶 DNMT1含量和酶活性相关, miR-152可被子 宫内膜癌 DNA甲基化变为沉默基因, 并且其与多种癌症的发生发展相关, 它是 一种肿瘤抑制 microRNA, 与子痫前期、 滋养细胞肿瘤、 膀胱癌、 胃肠癌、 卵巢 癌等诸多疾病相关; miR-185是一个长度为 22nt的 miRNA, 定位于人染色体 22ql 1.21, 在结肠癌、 胃癌、 食管癌、 肺癌、 肝癌等肿瘤的发生和侵袭等方面作为一 个抑癌基因发挥重要作用, 另外它一种甲基化相关的抑瘤性 miRNA, 可通过直 接靶向 DNMT1的表达而影响全基因组的甲基化水平, 进而调控某些基因的甲基 化修饰状态, 影响基因表达。 通过控制 miR-140、 miR-152和 miR-185的表达, 同 吋与其他药物协同作用, 能为治疗癌症提供新的表观遗传思路。 技术问题 [0003] miR-140 is closely related to the development of various diseases, such as bone and joint diseases, liver diseases, pituitary adenomas, testicular development, head and neck tumors, ovarian and breast diseases. miR-140 can inhibit the proliferation and invasion and metastasis of hepatocellular carcinoma by targeting TG FBR1 and other gene expression. miR-140 is highly expressed in articular cartilage and plays a vital role in the pathogenesis of osteoarthritis. Under the control of multiple mechanisms, m iR-140 plays an oncogene role in some tumors, and plays a tumor suppressor role in other tumors, and is associated with multiple tumor chemotherapy resistance; miR-152 is a kind of Functional miRNAs, studies have found that miR-152 is associated with methylation, such as methyltransferase DNMT1 content and enzyme activity, miR-152 can be methylated by endometrial cancer DNA into a silent gene, and its Related to the development of cancer, it is a tumor suppressor microRNA, which is associated with many diseases such as preeclampsia, trophoblastic tumor, bladder cancer, gastrointestinal cancer, ovarian cancer, etc. miR-185 is a 22 nt miRNA, localization Human chromosome 22ql 1.21 plays an important role as a tumor suppressor gene in the development and invasion of tumors such as colon cancer, gastric cancer, esophageal cancer, lung cancer, and liver cancer, and it also has a methylation phase. The inhibition of miRNA, may be through direct targeted expression DNMT1 level of methylation of the genome, and thus the regulation of the methylation status of certain modification genes, gene expression. By controlling the expression of miR-140, miR-152 and miR-185, the synergy with other drugs can provide new epigenetic ideas for the treatment of cancer. technical problem
[0004] MiRNA的功能研究主要通过 miRNA干扰和过表达技术完成。 现有 miRNA干扰 技术中, anti-miR和 antagomiR为瞬吋转染技术, 其干扰效果不能稳定保持, 而 m iRNA sponge效果远未达到最优, 现有技术缺乏一种干扰效果好且能实现长期稳 定干扰的技术。  [0004] Functional studies of MiRNAs are primarily accomplished through miRNA interference and overexpression techniques. Among the existing miRNA interference technologies, anti-miR and antagomiR are transient transfection techniques, and the interference effect cannot be stably maintained, while the mi RNA sponge effect is far from optimal. The prior art lacks a good interference effect and can achieve long-term effects. Stable interference technology.
[0005] Tough Decoy RNA (Tud RNA) 是一种新幵发出的 miRNA抑制手段, 其通过引 入双链 RNA对目标 miRNA进行吸附, 达到抑制 miRNA的目的。 由于弓 |入的 RNA 为双链并且带有茎环的二级结构, 因此其够抵抗胞内核酸酶的降解, 能长期、 稳定和高效地抑制 miRNA。  [0005] Tough Decoy RNA (Tud RNA) is a novel miRNA-inhibiting miRNA that inhibits miRNA by introducing double-stranded RNA to target miRNAs. Because the inserted RNA is double-stranded and has a secondary structure of stem-loops, it is resistant to intracellular nuclease degradation and inhibits miRNAs in a long-term, stable, and efficient manner.
[0006] 腺相关病毒 (AAV) 是一种非致病性人类细小病毒, 可广泛感染各种细胞包括 分裂期与非分裂期细胞, 因具有安全、 持久、 高效、 高特异性等特性受到广大 研究人员高度关注和青睐, 在生物学领域中被广泛使用。 以 AAV为基因治疗载 体极具潜在优势。 [0006] Adeno-associated virus (AAV) is a non-pathogenic human parvovirus that can infect a wide variety of cells, including mitotic and non-dividing cells, and is characterized by its safety, long-lasting, high-efficiency, and high specificity. Researchers are highly regarded and favored and are widely used in the field of biology. The use of AAV as a gene therapy vector has potential advantages.
问题的解决方案  Problem solution
技术解决方案  Technical solution
[0007] 本发明的目的是提供一种敲低 miR-140、 miR-152和 miR-185表达的重组腺相关 病毒。  [0007] It is an object of the present invention to provide a recombinant adeno-associated virus that knocks down the expression of miR-140, miR-152 and miR-185.
[0008] 为实现上述目的, 本发明采取的技术方案是: 一种敲低 miR-140、 miR-152和 mi [0008] In order to achieve the above object, the technical solution adopted by the present invention is: a knockdown of miR-140, miR-152 and mi
R-185表达的重组腺相关病毒是由下列方法构建得到的: The recombinant adeno-associated virus expressed by R-185 was constructed by the following methods:
[0009] a. [0009] a.
根据人 miR-140、 miR-152和 miR-185序列, 设计针对 miR-140、 1^11-152和1^11-18 5特异性的 Tud RNA序列, 构建重组质粒 pAKD-Tud-140-152-185, 并进行 DNA测 序分析;  Based on the human miR-140, miR-152 and miR-185 sequences, the Tud RNA sequences specific for miR-140, 1^11-152 and 1^11-18 5 were designed to construct the recombinant plasmid pAKD-Tud-140-152. -185, and performing DNA sequencing analysis;
[0010] b.将重组质粒 pAKD-Tud-140-152-185、 包装质粒 pAAV-RC和辅助质粒 pHelper 用磷酸钙法共转染 AAV-293细胞, 收获重组腺相关病毒 rAAV- Tud-140-152-185 , 采用定量 PCR方法对病毒进行滴度测定。  [0010] b recombinant plasmid pAKD-Tud-140-152-185, packaging plasmid pAAV-RC and helper plasmid pHelper co-transfected AAV-293 cells with calcium phosphate method, harvesting recombinant adeno-associated virus rAAV- Tud-140- 152-185, the titer of the virus was determined by quantitative PCR.
[0011] 所述的步骤 a中针对 miR-140、 miR-152和 miR-185特异性 Tud RNA序列为: 5'- GCCCAAGATGATCCTAGCGCCACCTTTTT -3,。 [0011] The Tud RNA sequence specific for miR-140, miR-152 and miR-185 in step a is: 5'- GCCCAAGATGATCCTAGCGCCACCTTTTT -3,.
[0012] 所述的步骤 a中在选定的靶点序列基础上添加 Kpn I和 Bg III内切酶的酶切位点序 列与转录终止序列, 合成完整的 Tud DNA序列: [0012] In step a, a Kpn I and Bg III endonuclease cleavage site sequence and a transcription termination sequence are added to the selected target sequence to synthesize a complete Tud DNA sequence:
[0013] Tud DNA-F: 5'- [0013] Tud DNA-F: 5'-
Figure imgf000004_0001
Figure imgf000004_0001
TTGGTGCCCAAGATGATCCTAGCGCCACCTTTTTGTAC -3'  TTGGTGCCCAAGATGATCCTAGCGCCACCTTTTTGTAC -3'
Tud DNA-R: 5,-  Tud DNA-R: 5,-
Figure imgf000004_0002
Figure imgf000004_0002
TTTCGGTCGGGGAGTTGATGATCCTAGCGCC -3,。  TTTCGGTCGGGGAGTTGATGATCCTAGCGCC -3,.
发明的有益效果  Advantageous effects of the invention
有益效果  Beneficial effect
[0015] 本发明构建了一种敲低 miR-140、 miR-152和 miR-185的重组腺相关病毒 rAAV-T ud-140-152-185 , 采用可以长期稳定表达目的蛋白以及高度的生物安全性的 8型 腺相关病毒 (AAV8) 为转导载体, 能在体内长期稳定表达 Tud RNA, 从而起到 敲低 miR- 140、 miR- 152和 miR- 185表达的作用。  The present invention constructs a recombinant adeno-associated virus rAAV-T ud-140-152-185 which knocks down miR-140, miR-152 and miR-185, and can stably express the target protein and high biosafety for a long time. The serotype 8 adeno-associated virus (AAV8) is a transduction vector that stably expresses Tud RNA in vivo for a long time, thereby knocking down the expression of miR-140, miR-152 and miR-185.
对附图的简要说明  Brief description of the drawing
附图说明  DRAWINGS
[0016] 图 1为定量 PCR检测各组细胞的 miRNA表达水平结果示意图, 其中, a. miR- 140 的表达情况, b. miR-152的表达情况, c. miR- 185的表达情况。 实施该发明的最佳实施例 1 is a schematic diagram showing the results of quantitative PCR detection of miRNA expression levels in each group of cells, wherein a. miR-140 expression, b. miR-152 expression, c. miR-185 expression. BEST MODE FOR CARRYING OUT THE INVENTION
本发明的最佳实施方式  BEST MODE FOR CARRYING OUT THE INVENTION
[0017] 根据下述实施例, 可以更好地理解本发明。 然而, 本领域的技术人员容易理解 , 实施例所描述的具体的物料配比、 工艺条件及其结果仅用于说明本发明, 而 不应当也不会限制权利要求书中所详细描述的本发明。 下述实施例中所用的方 法如无特别说明均为常规方法; 所述试剂如无特殊说明, 均为市售产品。 具体 步骤可参见: 《Molecular Cloning: A Laboratory Manual》 (Sambrook, J., Russell, David W., Molecular Cloning: A Laboratory Manual, 3rd edition, 2001, NY, Cold Spring Harbor) ° [0017] The present invention can be better understood from the following examples. However, those skilled in the art will readily appreciate that the specific material ratios, process conditions, and results described in the examples are merely illustrative of the invention and are not intended to limit the invention as described in the claims. . The methods used in the following examples are conventional methods unless otherwise specified; the reagents are commercially available products unless otherwise specified. Specific steps can be found in: "Molecular Cloning: A Laboratory Manual" (Sambrook, J., Russell, David W., Molecular Cloning: A Laboratory Manual, 3rd edition, 2001, NY, Cold Spring Harbor)
[0018] 实施例一: 构建敲氐 miR-140、 miR-152和 miR-185表达的重组腺相关病毒  Example 1: Construction of a recombinant adeno-associated virus expressed by miR-140, miR-152 and miR-185
[0019] 1、 构建重组质粒 pAKD-Tud-140-152-185 [0019] 1. Construction of recombinant plasmid pAKD-Tud-140-152-185
[0020] 根据 TuD RNA设计序列和 miRBase中提供的 miR-140、 1^11-152和1^11-185的序 列信息, 设计出针对 miR-140、 miR-152和 miR-185特异性 Tud RNA序列: 5'-  [0020] Based on the sequence information of miR-140, 1^11-152 and 1^11-185 provided in the TuD RNA design sequence and miRBase, the Tud RNA specific for miR-140, miR-152 and miR-185 was designed. Sequence: 5'-
Figure imgf000005_0001
Figure imgf000005_0001
GCCCAAGATGATCCTAGCGCCACCTTTTT -3,。 在选定的靶点序列基础上添加 GCCCAAGATGATCCTAGCGCCACCTTTTT -3,. Add based on the selected target sequence
Kpn I和 Bgl II内切酶的酶切位点序列与转录终止序列, 委托上海英骏生物技术 有限公司合成完整的 Tud DNA序歹 ij。 The cleavage site sequence and transcription termination sequence of Kpn I and Bgl II endonucleases were commissioned by Shanghai Yingjun Biotechnology Co., Ltd. to synthesize the complete Tud DNA sequence ij ij.
[0021] 进行 Tud DNA模板的退火, 经退火反应后, 形成两端带有 Kpn I和 Bgl II酶切 位点的双链寡核苷酸片段, 标记为 Tud-140-152-185。  [0021] The Tud DNA template was annealed, and after annealing, a double-stranded oligonucleotide fragment having a Kpn I and Bgl II restriction sites at both ends was formed, which was labeled Tud-140-152-185.
[0022] 取 pAKD-shRNA质粒载体, 利用 Kpn I和 Bgl II酶切使其线性化, 取适量产物进 行 1%琼脂糖凝胶电泳检测并进行回收。 按照连接反应体系将双链 DNA连接入酶 切载体, 连接后于 4 °C孵育过夜, 并转化至感受态大肠杆菌 DH5oc, 涂布平板后 培育过夜。 挑取单菌落进行培育并送至上海英骏生物技术进行测序。 培养测序 结果完全正确的菌, 并用 Promega质粒抽提试剂盒 (去内毒素) 提取 pAKD-Tud- 140-152-185质粒。 [0023] 2、 病毒包装、 纯化及滴度测定 [0022] The pAKD-shRNA plasmid vector was obtained by linear digestion with Kpn I and Bgl II, and an appropriate amount of the product was detected by 1% agarose gel electrophoresis and recovered. The double-stranded DNA was ligated into the restriction vector according to the ligation reaction system, ligated and incubated at 4 ° C overnight, and transformed into competent E. coli DH5oc, which was plated and incubated overnight. Single colonies were picked for cultivation and sent to Shanghai Yingjun Biotechnology for sequencing. The bacteria with the correct sequencing results were cultured, and the pAKD-Tud-140-152-185 plasmid was extracted using the Promega plasmid extraction kit (endotoxin). [0023] 2. Virus packaging, purification and titer determination
[0024] 常规方法进行 AAV-293细胞培养, 当细胞达到 70-80%融合吋采用磷酸钙法进 行病毒转染, 即可得到表达 Tud-140-152-185的 rAAV8, 并进行病毒的收集、 浓 缩和纯化。  [0024] AAV-293 cell culture is carried out by a conventional method, and when the cells reach 70-80% fusion, the calcium phosphate method is used for virus transfection, and rAAV8 expressing Tud-140-152-185 is obtained, and virus collection is performed. Concentrate and purify.
[0025] 采用定量 PCR的方法对病毒进行滴度测定。 通过检测病毒基因组中 rAAV载体 的基因组拷贝数来测定 rAAV的病毒颗粒数, 滴度单位用 vg/ml来表示, 即每 ml含 有的病毒基因组数 (Vims Genome) 。 将待测病毒样品用 DNase和 RNase于 37°C 消化 2〜3h, 提取病毒 DNA, 沸水浴 5min使之变性, 立即置于冰上 2min, 将病毒 样品与标准品做倍比稀释成不同浓度, 进行定量 PCR检测, 所用引物为: 上游: 5'-CCTTTCCGGGACTTTCGCTTT-3' , 下游: 5,-GCAGAATCCAGGTGGCAAC A-3,。  [0025] The virus was titrated by a quantitative PCR method. The number of viral particles of rAAV is determined by detecting the genomic copy number of the rAAV vector in the viral genome, and the titer unit is expressed in vg/ml, that is, the number of viral genomes per ml (Vims Genome). The virus sample to be tested was digested with DNase and RNase at 37 ° C for 2~3 h, and the virus DNA was extracted and denatured in a boiling water bath for 5 min, immediately placed on ice for 2 min, and the virus sample and the standard product were diluted to different concentrations. For quantitative PCR detection, the primers used were: upstream: 5'-CCTTTCCGGGACTTTCGCTTT-3', downstream: 5,-GCAGAATCCAGGTGGCAAC A-3.
[0026] 反应条件为: 94°C变性 15s, 52°C退火 30s, 72°C延伸 30s, 共进行 40循环。 PCR 结束后, 根据标准品绘制标准曲线并计算病毒样品滴度。 经计算, 病毒平均滴 度为 1.05x1012 vg/ml。  The reaction conditions were: denaturation at 94 ° C for 15 s, annealing at 52 ° C for 30 s, and extension at 72 ° C for 30 s, for a total of 40 cycles. After the end of the PCR, a standard curve was drawn based on the standard and the virus sample titer was calculated. The average virus titer was calculated to be 1.05x1012 vg/ml.
[0027] 实施例二: AAV转染 ACHN细胞  Example 2: AAV transfection ACHN cells
[0028] 接种 ACHN细胞于六孔板中, 每孔 1000000个细胞, 12h后细胞密度约为 50% , 分别取病毒液, 用 DMEM完全培养基 1000倍稀释病毒, 去除 6孔板中的培养 基, 加入含病毒的 DMEM完全培养基(含 10%胎牛血清), 24h  [0028] ACHN cells were inoculated into a six-well plate, 1000000 cells per well, and the cell density was about 50% after 12 hours. The virus solution was taken separately, and the virus was diluted 1000 times with DMEM complete medium to remove the medium in the 6-well plate. , add virus-containing DMEM complete medium (containing 10% fetal bovine serum), 24h
后弃去含病毒的 DMEM完全培养基, 更换新鲜的 DMEM  Discard the virus-containing DMEM complete medium and replace with fresh DMEM.
完全培养基, 继续培养 96 h。  Complete medium and continue to culture for 96 h.
[0029] 实施例三: 荧光定量 PCR检测 miRNA的表达水平变化  Example 3: Fluorescence quantitative PCR detection of changes in miRNA expression levels
[0030] 用 miRcute miRNA提取分离试剂盒提取正常 ACHN细胞和 TuD-140-152-185细胞 细胞的 miRNA, 然后用 S-Poly(T) hsa-miR-140 qPCR-assay primer set、 S-Poly(T) hsa-miR-152 qPCR-assay primer set和 S-Poly(T) hsa-miR-185 qPCR-assay primer set 试剂盒对 miRNA进行逆转录和加尾, 得到相应的 cDNA。 取 2种细胞的 cDNA各 2 为模板, 荧光定量 PCR检测 miR-140、 miR-152和 miR-185表达水平的变化, 实 验重复 3次, 每孔设置 3个平行样,以 snord 44作为内参。 结果如图 2所示, 可以看 到与 TuD-140-152-185细胞的 miR-140的表达水平比 ACHN细胞低 43<¾, miR-152 的表达水平比 ACHN细胞低 63%, miR-185的表达水平比 ACHN细胞低 48%。 差异 有统计学意义 (p<0.01) , 说明 TuD-140-152-185细胞株构建成功。 [0030] The miRNAs of normal ACHN cells and TuD-140-152-185 cells were extracted using the miRcute miRNA extraction and isolation kit, followed by S-Poly(T) hsa-miR-140 qPCR-assay primer set, S-Poly ( T) hsa-miR-152 qPCR-assay primer set and S-Poly(T) hsa-miR-185 qPCR-assay primer set kit for reverse transcription and tailing of miRNA to obtain the corresponding cDNA. The cDNA of each of the two cells was used as a template. The expression levels of miR-140, miR-152 and miR-185 were detected by real-time PCR. The experiment was repeated three times, and three parallel samples were set in each well, and snord 44 was used as an internal reference. The results are shown in Figure 2. It can be seen that the expression level of miR-140 in TuD-140-152-185 cells is 43<3⁄4 lower than that of ACHN cells, miR-152. The expression level was 63% lower than that of ACHN cells, and the expression level of miR-185 was 48% lower than that of ACHN cells. The difference was statistically significant (p<0.01), indicating that the TuD-140-152-185 cell line was successfully constructed.
工业实用性 Industrial applicability
本发明构建了一种敲低 miR-140、 miR-152和 miR-185的重组腺相关病毒 rAAV-T ud-140-152-185 , 采用可以长期稳定表达目的蛋白以及高度的生物安全性的 8型 腺相关病毒 (AAV8) 为转导载体, 能在体内长期稳定表达 Tud RNA, 从而起到 敲低 miR- 140、 miR- 152和 miR- 185表达的作用。  The present invention constructs a recombinant adeno-associated virus rAAV-T ud-140-152-185 which knocks down miR-140, miR-152 and miR-185, and has a long-term stable expression of the target protein and high biosafety. The adeno-associated virus (AAV8) is a transduction vector that stably expresses Tud RNA in vivo for a long time, thereby knocking down the expression of miR-140, miR-152 and miR-185.

Claims

权利要求书 Claim
[权利要求 1] 一种敲低 miR-140、 miR-152和 miR-185表达的重组腺相关病毒, 其特 征在于, 所述的重组腺相关病毒是由下列方法构建得到的: a.  [Claim 1] A recombinant adeno-associated virus which knocks down expression of miR-140, miR-152 and miR-185, characterized in that the recombinant adeno-associated virus is constructed by the following method: a.
根据人 miR-140、 miR-152和 miR-185序列, 设计针对 miR-140、 miR-1 52和 miR- 185特异性的 Tud  Tud specific for miR-140, miR-1 52 and miR-185 based on human miR-140, miR-152 and miR-185 sequences
RNA序歹 ij, 构建重组质粒 pAKD-Tud-140-152-185, 并进行 DNA测序 分析;  The RNA sequence ij ij, the recombinant plasmid pAKD-Tud-140-152-185 was constructed and subjected to DNA sequencing analysis;
b.将重组质粒 pAKD-Tud-140-152-185、 包装质粒 pAAV-RC和辅助质 粒 pHelper用磷酸钙法共转染 AAV-293细胞, 收获重组腺相关病毒 rAA V- Tud-140-152-185 , 采用定量 PCR方法对病毒进行滴度测定。  b. Recombinant plasmid pAKD-Tud-140-152-185, packaging plasmid pAAV-RC and helper plasmid pHelper were co-transfected into AAV-293 cells with calcium phosphate method, and recombinant adeno-associated virus rAA V- Tud-140-152- was harvested. 185. The titer of the virus was determined by a quantitative PCR method.
[权利要求 2] 根据权利要求 1所述的敲低 miR- 140、 miR- 152和 miR- 185表达的重组 腺相关病毒, 其特征在于, 所述的腺相关病毒载体的血清型为 8型。  [Claim 2] The recombinant adeno-associated virus which is expressed by knockdown of miR-140, miR-152 and miR-185 according to claim 1, wherein the serotype of the adeno-associated virus vector is type 8.
[权利要求 3] 根据权利要求 1所述的敲低 miR- 140、 miR- 152和 miR- 185表达的重组 腺相关病毒, 其特征在于, 步骤 a中针对 miR-140、 miR- 152和 miR- 18 5特异性 Tud RNA序列为: 5'- [Claim 3] The recombinant adeno-associated virus which knocks down expression of miR-140, miR-152 and miR-185 according to claim 1, wherein step a is directed to miR-140, miR-152 and miR- The 18 5 specific Tud RNA sequence is: 5'-
Figure imgf000008_0001
Figure imgf000008_0001
TAGCGCCACCTTTTT -3,。  TAGCGCCACCTTTTT -3,.
[权利要求 4] 根据权利要求 1所述的敲低 miR- 140、 miR- 152和 miR- 185表达的重组 腺相关病毒, 其特征在于, 步骤 a中在选定的靶点序列基础上添加 Kp nl和 Bglll内切酶的酶切位点序列与转录终止序列, 合成完整的 Tud DNA序歹 'J:  [Claim 4] The recombinant adeno-associated virus which knocks down miR-140, miR-152 and miR-185 expression according to claim 1, wherein step a adds Kp to the selected target sequence Nl and Bglll endonuclease cleavage site sequences and transcription termination sequences, synthesis of complete Tud DNA sequence 歹 'J:
Tud DNA-F: 5'- GATCCTAGCGCCACCTTTTTGTAC -3' Tud DNA-R: 5,-
Figure imgf000009_0001
Tud DNA-F: 5'- GATCCTAGCGCCACCTTTTTGTAC -3' Tud DNA-R: 5,-
Figure imgf000009_0001
TGATGATCCTAGCGCC -3' =  TGATGATCCTAGCGCC -3' =
PCT/CN2017/077603 2017-03-22 2017-03-22 Recombinant adeno-associated virus for knocking down expressions of mir-140, mir-152 and mir-185 WO2018170761A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/077603 WO2018170761A1 (en) 2017-03-22 2017-03-22 Recombinant adeno-associated virus for knocking down expressions of mir-140, mir-152 and mir-185

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/077603 WO2018170761A1 (en) 2017-03-22 2017-03-22 Recombinant adeno-associated virus for knocking down expressions of mir-140, mir-152 and mir-185

Publications (1)

Publication Number Publication Date
WO2018170761A1 true WO2018170761A1 (en) 2018-09-27

Family

ID=63584887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/077603 WO2018170761A1 (en) 2017-03-22 2017-03-22 Recombinant adeno-associated virus for knocking down expressions of mir-140, mir-152 and mir-185

Country Status (1)

Country Link
WO (1) WO2018170761A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
B SONG ET AL.,: "Mechanism of chemoresistance mediated by miR-140 in human osteo- sarcoma and colon cancer cells", ONCOGENE, vol. 28, no. 46, 7 September 2009 (2009-09-07), pages 4065 - 4074, XP055022150, ISSN: 0950-9232 *
DATABASE Nucleotide 11 December 2014 (2014-12-11), YU M.: "Homo sapiens microRNA 185 (MIR185), microRNA", XP055540744, retrieved from NCBI Database accession no. NR_029706 *
DATABASE Nucleotide 21 May 2015 (2015-05-21), YAO Y.: "Homo sapiens microRNA 152 (MIR152), microRNA", XP055540739, retrieved from NCBI Database accession no. NR_029687 *
DATABASE Nucleotide 21 May 2015 (2015-05-21), YUAN L: "Homo sapiens microRNA 140 (MIR140), microRNA", XP055608377, retrieved from NCBI Database accession no. NR_029681 *
LINWENSI ZHU: "The Structure and Clinical Roles of MicroRNA in Colorectal Cancer", GASTROENTEROLOGY RESEARCH AND PRACTICE, 31 December 2016 (2016-12-31), XP055540703, ISSN: 1687-630X *

Similar Documents

Publication Publication Date Title
CN107502608A (en) Construction method and application for sgRNA, ALDH2 gene delection cell line for knocking out people&#39;s ALDH2 genes
EP3778892A1 (en) Novel small activating rna
CN105132424A (en) MicroRNA inhibitor, microRNA inhibitor expression vector, building method of microRNA inhibitor expression vector and application of microRNA inhibitor expression vector
CN101402945A (en) Process for producing small RNA recombinant birds adeno-associated virus for expression of infectivity resistant bursa of fabricius disease virus
CN109402269B (en) Application of reagent for detecting miRNA-217-5p in preparation of duck intestinal stress detection reagent
Sun et al. Construction of lentivirus-based inhibitor of hsa-microRNA-338-3p with specific secondary structure
ES2708750T3 (en) Sequences of TTV miRNA as an early marker for the future development of cancer and as a target for the treatment and prevention of cancer
US20160160216A1 (en) Ttv mirna sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention
WO2018170761A1 (en) Recombinant adeno-associated virus for knocking down expressions of mir-140, mir-152 and mir-185
CN104195153B (en) A kind of Bicistronic mRNA coexpression gene transporter and preparation method
WO2019000151A1 (en) Recombinant adeno-associated virus for simultaneously inhibiting expressions of three micrornas
WO2019000143A1 (en) Recombinant adeno-associated virus knocking down mirna expression
CN111228292B (en) Application of human TPT1/TCTP gene in preparation of antitumor drugs
WO2018170760A1 (en) Recombinant adeno-associated virus for targeted inhibition of expressions of mir-140, mir-148a and mir-424
WO2018165929A1 (en) Dual mirna inhibitory expression vector, construction method and application thereof
CN110964727A (en) shRNA lentiviral expression vector construction method for specifically inhibiting c-myc gene expression and application thereof
CN110564743A (en) CircR-UQCC1 gene of Lianshan cattle, over-expression vector, construction method and application thereof
CN103194450A (en) Method for increasing activity of myogenin (MyoG) gene promoter
CN102813926A (en) Application of miR-7 expression inhibitor in preparing medicines used for treating systemic lupus erythematosus
CN103898137B (en) A kind of plasmid containing MALAT1 gene 3&#39;UTR sequence and double luciferase reporter gene and application thereof
CN106591311B (en) Nucleic acids and uses thereof
CN107760717A (en) Sheep TNPO1 gene dual luciferase reporter gene carrier and its construction method and application
CN103589723B (en) A kind of Newborn recombinant promoter and application thereof
WO2018170753A1 (en) Tud rna for knocking down mirna-29a, mirna-152, and mirna-185, and application thereof
WO2018170759A1 (en) Recombinant ad-140-148a-185-tud adenovirus, and construction and application thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17901604

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17901604

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载